Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10041073 Reduced size self-delivering RNAi compounds

Patent 10041073 was granted and assigned to Rxi Pharmaceuticals Corporation on August, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
‌
Rxi Pharmaceuticals Corporation
0
Date Filed
March 23, 2011
0
Date of Patent
August 7, 2018
0
Patent Application Number
13069780
0
Patent Citations Received
‌
US Patent 11926828 Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
0
‌
US Patent 10913948 RNA interference in dermal and fibrotic indications
0
‌
US Patent 10934550 Immunotherapy of cancer
‌
US Patent 11584933 RNA interference in ocular indications
‌
US Patent 11001845 Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)
‌
US Patent 11021707 Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
‌
US Patent 11254940 Inhibition of MAP4K4 through RNAi
‌
US Patent 11279934 Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
‌
US Patent 11667915 RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
0
‌
US Patent 11396654 Neutral nanotransporters
•••
Patent Inventor Names
Dmitry Samarsky
0
Tod M. Woolf
0
William Salomon
0
Anastasia Khvorova
0
James Cardia
0
Joanne Kamens
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
10041073
0
Patent Primary Examiner
‌
J. E. Angell
0

Find more entities like US Patent 10041073 Reduced size self-delivering RNAi compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.